Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.

doi:10.1007/s13318-016-0324-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.

European journal of drug metabolism and pharmacokinetics - 1 Feb 2017

Danielak Dorota, Karaźniewicz-Łada Marta, Wiśniewska Karolina, Bergus Piotr, Burchardt Paweł, Komosa Anna, Główka Franciszek

Abstract excerpt

BACKGROUND AND OBJECTIVES: Resistance to the antiplatelet treatment with clopidogrel has both genetic and non-genetic causes. Polymorphic variants of cytochrome P450 3A4 isoenzyme involved in the bioactivation of clopidogrel might have an influence on responsiveness to the drug. The aim of this study was to evaluate the influence of CYP3A4*1G (IVS10+12G>A, rs2242480) on the pharmacokinetics and pharmacodynamics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to Drug Interactions

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 26891871
DOI: 10.1007/s13318-016-0324-7
PMCID: PMC5306247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel.PMID 26891871Read ↗

Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.Semantic proximity Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.Semantic proximity Read ↗

Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Semantic proximity Read ↗

The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.Semantic proximity Read ↗

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Semantic proximity Read ↗

Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment.Semantic proximity Read ↗

Genetic and nongenetic factors influencing the response to clopidogrel.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Pharmacogenetics of Clopidogrel: An Unresolved Issue.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.